Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
MEDX
Horizon Kinetics Medical ETF
36.5
2
USD
-0.01%
Market Price
Sector:
Financial
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
-1.35%
Monthly Change
+1.98%
6 month change
+7.25%
Year Change
+25.54%
Previous Close
37.0
2
Open
36.5
2
Low
36.5
2
High
36.5
2
Volume
2
Markets
US ETFs
MEDX
1D
1W
1M
3M
6M
YTD
1Y
5Y
Open full chart
Overview
All holdings
Heatmap
Top holdings
Market Value
Shares
Weight %
LLY
Eli Lilly & Co
3.52 M
2 936.00
18.46%
US BANK MMDA - USBGFS 7
1.75 M
1.75 M
9.19%
ABBV
AbbVie Inc
1.69 M
6 712.00
8.85%
NVS
Novartis AG
1.31 M
8 388.00
6.89%
JNJ
Johnson & Johnson
1.07 M
4 200.00
5.59%
ALKS
Alkermes PLC
1.05 M
20.13 K
5.53%
A
AZN
AstraZeneca PLC
950.94 K
5 015.00
4.98%
IONS
Ionis Pharmaceuticals Inc
864.58 K
10.90 K
4.53%
BMY
Bristol-Myers Squibb Co
843.79 K
14.64 K
4.42%
MRK
Merck & Co Inc
754.55 K
5 872.00
3.96%
AMGN
Amgen Inc
746.69 K
2 062.00
3.91%
ALNY
Alnylam Pharmaceuticals Inc
652.63 K
2 168.00
3.42%
BIIB
Biogen Inc
588.98 K
2 726.00
3.09%
PFE
Pfizer Inc
545.36 K
22.65 K
2.86%
GSK
GSK PLC
516.13 K
9 846.00
2.71%
CRSP
CRISPR Therapeutics AG
503.30 K
9 228.00
2.64%
REGN
Regeneron Pharmaceuticals Inc
392.83 K
630.00
2.06%
BEAM
Beam Therapeutics Inc
287.88 K
8 388.00
1.51%
GALT
Galectin Therapeutics Inc
217.93 K
46.97 K
1.14%
NTLA
Intellia Therapeutics Inc
212.92 K
12.58 K
1.12%
1
2
News
Medmix FY25 revenue falls, dividend cut 80%; shares down 17%
Medmix FY 2025 slides: margins surge 90bps as revenue falls 7.4%
Earnings call transcript: Medmix sees margin growth amid revenue dip in H2 2025
Medical ETF (MEDX) Touches New 52-Week High
Stifel initiates coverage on Medmix stock with Buy rating, CHF14.50 target
Eli Lilly Hits $1 Trillion Milestone: ETFs to Invest in
Horizon Kinetics Q3 2025 Commentary (HKHC)
ETFs in Focus on Eli Lilly's Solid Q2 Earnings, Weak Obesity Data